IShares MSCI USA Index Fund (EUSA)

QUOTE AND NEWS
GenEng News  May 10  Comment 
The European Commission granted accelerated approval for EUSA Pharma’s anti-GD2 monoclonal antibody dinutuxumab beta as a treatment for children aged over 12 months with high-risk neuroblastoma. The drug was originally developed by Austrian...
Benzinga  Mar 1  Comment 
EUSA Pharma, a newly-established specialty pharmaceutical business, and AVEO Oncology (NASDAQ: AVEO) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for tivozanib for the first-line...
Benzinga  Dec 21  Comment 
• AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) has announced a partnership with EUSA Pharma granting EUSA exclusive European rights to tivozanib . • The deal could reportedly generate nearly $400 million for AVEO . • AVEO CEO...
GenEng News  Dec 21  Comment 
AVEO Oncology has granted EUSA Pharma European rights to tivozanib for advanced renal cell carcinoma (RCC), the companies said today, in a deal that could generate up to $396.5 million-plus for AVEO. The deal includes additional territories...
Benzinga  Dec 21  Comment 
AVEO Oncology (NASDAQ: AVEO) and EUSA Pharma, a newly-established specialty pharmaceutical business with global reach, today announced an exclusive license agreement in which AVEO has granted EUSA Pharma European rights to tivozanib for the...
CNNMoney.com  Aug 29  Comment 
Our annual list of high achievers is a guide to the most vibrant part of corporate America and beyond.
StreetInsider.com  Jun 12  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Jazz+Pharma+%28JAZZ%29+Closes+EUSA+Pharma+Purchase%2C+Sees+Deal+Adding+25-30cShare+in+FY12/7511027.html for the full story.
Benzinga  Apr 26  Comment 
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and EUSA Pharma Inc. today announced that the companies have signed a definitive agreement under which Jazz Pharmaceuticals has agreed to acquire EUSA Pharma, a privately-held, specialty pharmaceutical...




RELATED WIKI ARTICLES
 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki